HK Stock Market Move | Joinn Laboratories (06127) has seen a more than 3% increase recently, as it has assisted Yikexin Technology in innovating the dual-specificity antibody YK012, which has been approved by the US FDA for investigational new drug (IND) application.

Joinn Laboratories (06127) rose more than 3%, reaching a 3.6% increase at the time of publication, with a price of 19.87 Hong Kong dollars and a turnover of 25,749,900 Hong Kong dollars. In terms of news, according to Joinn Laboratories official Weibo account, recently, the innovative bispecific antibody YK012 targeting CD19/CD3 developed by Icell Keimei Science Technology has officially received clinical trial approval (IND) from the Food and Drug Administration (FDA) in the United States for the treatment of primary membranous nephropathy (pMN). This is the world's first T-cell engager (TCE) bispecific drug approved for this indication, marking a synchronous breakthrough in the field of autoimmune diseases in China and the United States. Joinn Laboratories, as a non-clinical CRO partner of Icell Keimei Science Technology, fully participated in the non-clinical trial processes of the YK012 project, including pharmacokinetic services and toxicology experiments. It is reported that the development of YK012 is based on Icell Keimei Science Technology's dual-center layout of "Beijing headquarters + wholly-owned subsidiary Excyte LLC in the United States". After the FDA IND approval, the company will gradually initiate international multi-center clinical research, complementing the data from the multi-center trials already underway in China (led by Professor Zhao Minghui of Peking University First Hospital) and accelerating the global development process.